Inspira Technologies Oxy BHN (IINN) AI Stock Analysis

• Market Cap: $39.45M
• Dividend Yield: N/A
• Average Volume (3M): 1.31M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.59
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 37
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Devices
• EPS (TTM): N/A
• Shares Outstanding: 25,619,276
• 10 Day Avg. Volume: 2,181,983
• 30 Day Avg. Volume: 1,306,519
• PEG Ratio: 0.04
• Price to Book (P/B): 1.09
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.81
• Enterprise Value/Market Cap: 0.22
• Enterprise Value/Revenue: -0.61
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.19
• 1Y Price Target: $2.00
• Price Target Upside: 29.87% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 35 Underperform
• Price Target: ―

The overall stock score reflects significant financial instability, as indicated by ongoing losses and reliance on external funding. The technical analysis shows bearish sentiment, with the stock under pressure. Valuation is challenging due to negative earnings and lack of dividend yield, making the stock less appealing to investors.

Inspira Technologies Oxy BHN Business Overview & Revenue Model

Company Description

Inspira Technologies Oxy BHN (IINN) is a medical technology company specializing in respiratory care solutions. The company focuses on developing and commercializing innovative products aimed at improving patient outcomes in the treatment of respiratory conditions. Its core product is the ART (Augmented Respiratory Technology) system, designed to provide early intervention and prevent the need for mechanical ventilation in patients with respiratory failure. Inspira Technologies operates within the healthcare and medical device sectors, with a commitment to advancing respiratory care technology.

How the Company Makes Money

Inspira Technologies Oxy BHN generates revenue primarily through the sale and distribution of its proprietary medical devices, particularly the ART system. The company targets hospitals and healthcare facilities as its primary customers, offering them advanced respiratory care solutions to enhance patient treatment. Revenue is also derived from service agreements and maintenance contracts associated with their devices. Additionally, Inspira Technologies may engage in strategic partnerships with healthcare providers and distributors to expand its market reach and enhance its product offerings, contributing to its overall earnings.

Inspira Technologies Oxy BHN Financial Statement Overview

Summary

Inspira Technologies Oxy BHN is facing substantial financial challenges, with no revenue generation and ongoing losses. The balance sheet shows marginal improvements but still indicates potential liquidity and leverage issues. Cash flow analysis reveals a high dependency on external financing to sustain operations, which poses a significant risk to financial stability.

Income Statement

The company's income statement shows significant challenges. With no revenue generation over the analyzed periods, the company relies heavily on financing activities. The net income remains negative, indicating ongoing losses. The absence of revenue growth and consistent net losses are major concerns.

Balance Sheet

The balance sheet reflects a slight improvement in the financial position with a positive stockholders' equity in recent years. However, the debt-to-equity ratio has fluctuated due to inconsistent equity values and ongoing liabilities. The company's assets are limited, with cash forming a significant portion of its total assets, indicating potential liquidity constraints.

Cash Flow

Cash flows are under pressure with negative free cash flow consistently reported, reflecting higher cash outflows than inflows. Operating cash flow remains negative, highlighting the company's struggle to generate cash from operations. The reliance on financing cash flows indicates the company is dependent on external funding to support its operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	-4.68M	0.00	0.00
Gross Profit	0.00	0.00	-406.00K	-5.04M	-218.00K	-203.00K
EBITDA	-11.11M	-11.10K	-10.87M	-14.68M	-16.72M	-6.96M
Net Income	-10.92M	-11.05K	-11.29M	-4.00M	-16.96M	-7.23M
Balance Sheet
Total Assets	9.31M	8.07M	9.31M	16.01M	25.87M	987.00K
Cash, Cash Equivalents and Short-Term Investments	7.36M	5.78M	7.36M	13.90M	23.75M	496.00K
Total Debt	588.00K	655.00K	878.00K	1.46M	1.48M	1.92M
Total Liabilities	3.57M	3.75M	3.57M	3.19M	5.52M	2.69M
Stockholders Equity	5.74M	4.32M	5.74M	12.82M	20.35M	-1.70M
Cash Flow
Free Cash Flow	1.02K	-9.54M	-9.96M	-7.68M	-8.05M	-1.90M
Operating Cash Flow	1.02K	-9.37M	-9.76M	-7.38M	-7.88M	-1.88M
Investing Cash Flow	0.00	1.49M	4.59M	-7.25M	-246.00K	-26.00K
Financing Cash Flow	0.00	7.90M	3.45M	-399.00K	30.42M	2.29M

Inspira Technologies Oxy BHN Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.54
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IINN, the sentiment is Positive. The current price of 1.54 is above the 20-day moving average (MA) of 0.89, above the 50-day MA of 0.70, and above the 200-day MA of 0.96, indicating a bullish trend. The MACD of 0.17 indicates Negative momentum. The RSI at 81.30 is Negative, neither overbought nor oversold. The STOCH value of 86.51 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IINN.

Inspira Technologies Oxy BHN Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VREX	62 Neutral	$346.94M	―	-7.46%	―	-3.31%	-199.23%
Sector *	52 Neutral	$7.45B	0.27	-61.87%	2.30%	16.62%	1.04%
BMRA	49 Neutral	$8.66M	―	-72.70%	―	5.05%	26.13%
CTSO	46 Neutral	$64.49M	―	-94.65%	―	-5.86%	50.76%
CODX	40 Underperform	$8.80M	―	-56.80%	―	-91.22%	11.84%
IINN	35 Underperform	$39.45M	―	-196.69%	―	―	―
MOVE	23 Underperform	$4.75M	―	-439.23%	―	―	56.73%